Developer docs
API playgroundTry for free, no card

Search company profiles

Oxford StemTech

Full company profile

uuid000qz44

Namestring
Oxford StemTech
Legal namestring
Oxford StemTech
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Oxford StemTech is a privately held UK biotechnology company founded in 2020 and headquartered at The Oxford Science Park in Oxford. The company is built around its proprietary ReproPlex™ platform for large-scale induced Pluripotent Stem Cell (iPSC) reprogramming, which it markets as achieving 98% efficiency using non-integrating methods and capable of processing 100+ donors in 3-4 months. The founders — Prof. Zameel Cader (Co-Founder and Director), Dr. Satyan Chintawar (Co-Founder and COO), and Dr. Galbha Duggal (Co-Founder and CSO) — are University of Oxford-affiliated experts in stem cell biology, neuroscience, and neurology, and the company's scientific positioning leans heavily on this academic credibility.

The service portfolio covers the end-to-end iPSC workflow: PBMC isolation, ReproPlex™ reprogramming, comprehensive quality control (SNP karyotyping, pluripotency markers, mycoplasma testing, STR authentication, trilineage differentiation — GLP-compliant with full documentation), differentiation into neural and other lineages, CRISPR genome engineering, an iPSC repository of disease-specific lines (autism, bipolar disorder, diabetes, migraine, pain channelopathies, Alzheimer's, Parkinson's, and healthy controls), and a bespoke drug discovery platform focused on neurological disorders and pain established in 2022. Advanced offerings include cerebral organoids and assembloids (scaled in 2025), proprietary CGRP releasing peptidergic nociceptor models, and multi-electrode array (MEA) assays for phenotypic and target-based screening.

Commercially, Oxford StemTech operates a fee-for-service, quote-based professional services model with direct B2B engagement targeting research institutions, pharmaceutical companies, and biotechnology startups. GTM is consultative and partnership-driven, with all pricing bespoke and not publicly disclosed, no minimum project size, and global service scope via direct sales (no resellers). Revenue is not publicly disclosed, no venture capital funding rounds have been announced, and the company has received non-dilutive UK government support in the form of an Innovate UK Biomedical Catalyst grant and an MRC Node grant in 2024.

Short descriptiontext

Oxford StemTech is a UK-based biotechnology company that provides fee-for-service iPSC reprogramming, differentiation, quality control, CRISPR editing, and neurological drug discovery services to academic researchers, pharmaceutical firms, and biotech startups using its proprietary ReproPlex™ platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC reprogramming services, stem cell biology services, drug discovery services, CRISPR genome engineering, cell-based assay services
Industry1 code
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Stem Cell Research Services (iPSC Contract Research)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model7 records
1iPSC Reprogramming Services
TypeProfessional Services
Description

Fee-for-service reprogramming of patient donor samples into iPSCs using the ReproPlex™ platform. Pricing based on sample type and project scale. Delivered within 3-4 months for large-scale projects.

oxfordstemtech.com
2Bespoke Drug Discovery Services
TypeProfessional Services
Description

Collaborative, partnership-driven drug discovery services for neurological disorders. Includes custom iPSC-derived neurons and glia, disease modeling (monolayer, organoid, assembloids), phenotypic and target-based screening, and MEA assays. Engagements range from target validation through lead optimisation.

oxfordstemtech.com
3iPSC Quality Control Services
TypeProfessional Services
Description

Quality control testing for iPSC lines including Bespoke QC, Standard QC, and Complete QC packages. Provides comprehensive testing ensuring pluripotent nature and genomic stability with full documentation.

oxfordstemtech.com
4iPSC Differentiation Services
TypeProfessional Services
Description

Differentiation services transforming pluripotent cells into specialised cell types including neural lineage (cortical, dopaminergic, motor, sensory, GABAergic, glutamatergic neurons; astrocytes, microglia, oligodendrocytes), macrophages, endothelial cells, pericytes, and smooth muscle cells.

oxfordstemtech.com
5PBMC Isolation Service
TypeProfessional Services
Description

Standardised peripheral blood mononuclear cell isolation delivering high-quality, high-purity cells for downstream research applications including iPSC reprogramming. Successful isolation within 48 hours of blood withdrawal.

oxfordstemtech.com
6CRISPR Genome Engineering Services
TypeProfessional Services
Description

Precision CRISPR genome editing in human iPSCs including gene knockout and isogenic controls, point mutation introduction or correction, reporter cell line generation, large insertions and deletions, regulatory DNA modifications, with comprehensive off-target and QC analysis.

oxfordstemtech.com
7iPSC Repository
TypeOne Time License
Description

Access to characterised iPSC lines from repository for accelerated research. Collection includes lines from autism, bipolar disorder, diabetes, migraine, pain channelopathies, monogenic and sporadic Alzheimer's disease, monogenic and sporadic Parkinson's disease, and healthy controls.

oxfordstemtech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details3 tiers
1Bespoke QC - Tailored quality control package for basic iPSC characterisation
ModelOtherBilling cadenceMulti-year contract
Notes

Includes morphology assessment, pluripotency assessment, and freeze-thaw viability. Customized to specific project needs.

oxfordstemtech.com
2Standard QC - Comprehensive package for most research applications
ModelOtherBilling cadenceMulti-year contract
Notes

All core iPSC QC tests, SNP karyotyping analysis, and STR authentication. Most popular tier.

oxfordstemtech.com
3Complete QC - Full characterisation for publication-ready iPSC lines
ModelOtherBilling cadenceMulti-year contract
Notes

All Standard QC tests plus trilineage differentiation and extended documentation.

oxfordstemtech.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1ReproPlex™
Description

Standardized iPSC reprogramming and characterization platform for generating high-quality induced pluripotent stem cells for research and drug discovery.

oxfordstemtech.com
Core offering1 text field

Oxford StemTech provides fee-for-service induced pluripotent stem cell (iPSC) reprogramming, differentiation, quality control, CRISPR genome engineering, PBMC isolation, and bespoke neurological drug discovery support using its proprietary ReproPlex™ platform, cerebral organoids, assembloids, and multi-electrode array assays. The company sells these services directly to research institutions, pharmaceutical companies, and biotechnology startups on a project-quoted basis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 98% reprogramming efficiency with non-integrating methods
+3 more records
Product overview1 text field

Oxford StemTech provides a comprehensive, end-to-end suite of iPSC-based services built around their proprietary ReproPlex™ platform. The portfolio spans the entire iPSC workflow: PBMC isolation feeds into ReproPlex™ reprogramming, which is followed by iPSC Quality Control and iPSC Differentiation services. The platform is complemented by CRISPR Genome Engineering for gene editing, an iPSC Repository of pre-characterized disease-specific lines, and Bespoke Drug Discovery services for neurological disorders utilizing 2D monolayer, 3D organoid, and assembloid models.

Product and service7 records
1ReproPlex™ iPSC Reprogramming
CategoryiPSC Reprogramming Services
Description

Proprietary, large-scale induced pluripotent stem cell reprogramming service accepting blood (PBMCs, T cells, monocytes), skin biopsies (dermal fibroblasts), and other samples (keratinocytes, brain and intestinal fibroblasts), with reported 98% efficiency and 3–4 month delivery for 100+ donor projects. It is sold to research institutions, pharmaceutical companies, and biotechs needing scalable, high-quality iPSC generation.

2Bespoke Drug Discovery
CategoryDrug Discovery Services
Description

Custom, partnership-driven drug discovery engagement for neurological and pain disorders, spanning target validation through lead optimisation and using iPSC-derived neurons and glia, monolayer and 3D organoid/assembloid disease models, phenotypic and target-based screening, and multi-electrode array assays. It is delivered to pharmaceutical and biotechnology partners seeking human-relevant cell models for CNS drug discovery.

3iPSC Quality Control
CategoryCell Quality Control Services
Description

Comprehensive quality control testing services for iPSC lines covering SNP karyotyping and copy number analysis, pluripotency marker assessment (OCT4, SOX2, NANOG, TRA-1-60, SSEA-4), mycoplasma testing, freeze-thaw viability, STR authentication, and trilineage differentiation, offered in Bespoke, Standard, and Complete QC packages with GLP-compliant documentation. It is sold to researchers and pharma partners requiring publication-grade, traceable cell lines.

4iPSC Differentiation
CategoryCell Differentiation Services
Description

Expert differentiation service transforming iPSCs into specialised cell types, including neural lineages (cortical, dopaminergic, motor, sensory, GABAergic, and glutamatergic neurons; astrocytes, microglia, oligodendrocytes), macrophages, endothelial cells, pericytes, and smooth muscle cells, with cerebral organoids and assembloid 3D brain models. It is sold to researchers and pharma partners needing disease-relevant human cell models.

5PBMC Isolation Service
CategorySample Preparation Services
Description

Standardised peripheral blood mononuclear cell (PBMC) isolation delivering high-purity, high-viability cells within 48 hours of blood withdrawal for use in iPSC reprogramming and downstream research applications. It is sold to laboratories needing reliable input material for stem cell workflows.

6CRISPR Genome Engineering
CategoryGenome Engineering Services
Description

Precision CRISPR gene editing service in human iPSCs covering gene knockouts and isogenic controls, point mutation introduction or correction, reporter cell line generation, large insertions and deletions, and regulatory DNA modifications, with comprehensive off-target and quality control analysis. It is sold to biotech, pharma, and academic partners for disease modelling, target validation, and precision medicine research.

7iPSC Repository
CategoryCell Line Repository / Catalog
Description

Access to a collection of characterised iPSC lines from autism, bipolar disorder, diabetes, migraine, pain channelopathies, monogenic and sporadic Alzheimer's and Parkinson's disease, and healthy controls, enabling accelerated research timelines through off-the-shelf patient-specific lines. It is sold to academic and industry researchers needing ready-to-use, disease-specific iPSC lines.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Acquired by Fujifilm in 2015, CDI is a leading commercial iPSC provider offering iPSC-derived cell lines and services across multiple tissue types. Directly comparable to Oxford StemTech's reprogramming and differentiation services, but with substantially greater scale and capital backing.

TypeDirect peer
Description

UK-based provider of iPSC-derived cell types and custom iPSC services for neuroscience and drug discovery. Closely comparable in therapeutic focus (neuroscience) and service offering (iPSC-derived neurons, glia, custom reprogramming), making it Oxford StemTech's most direct competitor.

TypeDirect peer
Description

UK-based contract research organization specializing in iPSC-derived cell models and assay services for drug discovery, with strong focus on ophthalmology, kidney, and CNS models. Direct peer in geography, business model (CRO services), and iPSC disease modeling.

TypeEmerging player
Description

UK-based synthetic biology company providing iPSC-derived human cells at scale for research and drug discovery using proprietary transcription factor-based reprogramming. Comparable in iPSC focus and UK base, but with stronger venture funding and broader cell-type portfolio.

TypeDirect peer
Description

Specializes in iPSC-derived neural cells and neurological disease modeling services, closely aligned with Oxford StemTech's neuroscience/pain focus. Both offer custom neuronal differentiation and drug screening assays for CNS research.

TypeBroad incumbent
Description

Established Japanese-headquartered provider of iPSC services, reagents, and drug discovery offerings. Comparable iPSC reprogramming and disease modeling services, with a more global footprint and broader product catalog than Oxford StemTech.

TypeBroad incumbent
Description

Through its Cell Therapy & iPSC services, Thermo Fisher offers large-scale iPSC reprogramming, differentiation, and characterization services globally. Indirect competitor in the same iPSC service category but as part of a much broader life-sciences portfolio.

TypeBroad incumbent
Description

Global CDMO offering cell therapy and iPSC-related services to pharma and biotech. Comparable at the high end of large-scale iPSC manufacturing and differentiation, but with vastly greater scale, regulatory depth, and pharma relationships.

TypeEmerging player
Description

Academic and commercial iPSC cores provide reprogramming, banking, and differentiation services for researchers. Comparable as alternative service providers, particularly for academic customers who might otherwise use Oxford StemTech.

TypeOthers
Description

Major supplier of cell culture media, reagents, and primary cell products supporting iPSC and stem cell research. Not a direct service competitor but an enabling supplier whose products are used in iPSC workflows alongside Oxford StemTech's services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oxford StemTech

Stem Cell Research Services (iPSC Contract Research)oxfordstemtech.com

Oxford StemTech is a UK-based biotechnology company that provides fee-for-service iPSC reprogramming, differentiation, quality control, CRISPR editing, and neurological drug discovery services to academic researchers, pharmaceutical firms, and biotech startups using its proprietary ReproPlex™ platform.

What Oxford StemTech does

Oxford StemTech is a privately held UK biotechnology company founded in 2020 and headquartered at The Oxford Science Park in Oxford. The company is built around its proprietary ReproPlex™ platform for large-scale induced Pluripotent Stem Cell (iPSC) reprogramming, which it markets as achieving 98% efficiency using non-integrating methods and capable of processing 100+ donors in 3-4 months. The founders — Prof. Zameel Cader (Co-Founder and Director), Dr. Satyan Chintawar (Co-Founder and COO), and Dr. Galbha Duggal (Co-Founder and CSO) — are University of Oxford-affiliated experts in stem cell biology, neuroscience, and neurology, and the company's scientific positioning leans heavily on this academic credibility.

The service portfolio covers the end-to-end iPSC workflow: PBMC isolation, ReproPlex™ reprogramming, comprehensive quality control (SNP karyotyping, pluripotency markers, mycoplasma testing, STR authentication, trilineage differentiation — GLP-compliant with full documentation), differentiation into neural and other lineages, CRISPR genome engineering, an iPSC repository of disease-specific lines (autism, bipolar disorder, diabetes, migraine, pain channelopathies, Alzheimer's, Parkinson's, and healthy controls), and a bespoke drug discovery platform focused on neurological disorders and pain established in 2022. Advanced offerings include cerebral organoids and assembloids (scaled in 2025), proprietary CGRP releasing peptidergic nociceptor models, and multi-electrode array (MEA) assays for phenotypic and target-based screening.

Commercially, Oxford StemTech operates a fee-for-service, quote-based professional services model with direct B2B engagement targeting research institutions, pharmaceutical companies, and biotechnology startups. GTM is consultative and partnership-driven, with all pricing bespoke and not publicly disclosed, no minimum project size, and global service scope via direct sales (no resellers). Revenue is not publicly disclosed, no venture capital funding rounds have been announced, and the company has received non-dilutive UK government support in the form of an Innovate UK Biomedical Catalyst grant and an MRC Node grant in 2024.

Oxford StemTech firmographics

Firmographics
Name
Oxford StemTech
Legal name
Oxford StemTech
Website
https://oxfordstemtech.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Oxford StemTech is a UK-based biotechnology company that provides fee-for-service iPSC reprogramming, differentiation, quality control, CRISPR editing, and neurological drug discovery services to academic researchers, pharmaceutical firms, and biotech startups using its proprietary ReproPlex™ platform.
Ownership category
akta.pro rank

Oxford StemTech industry classification

Industry
Product category
Stem Cell Research Services (iPSC Contract Research)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • IPSC reprogramming services
  • Stem cell biology services
  • Drug discovery services
  • CRISPR genome engineering
  • Cell-based assay services

Where Oxford StemTech is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Oxford StemTech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. iPSC Reprogramming Services: Fee-for-service reprogramming of patient donor samples into iPSCs using the ReproPlex™ platform. Pricing based on sample type and project scale. Delivered within 3-4 months for large-scale projects.
  2. Bespoke Drug Discovery Services: Collaborative, partnership-driven drug discovery services for neurological disorders. Includes custom iPSC-derived neurons and glia, disease modeling (monolayer, organoid, assembloids), phenotypic and target-based screening, and MEA assays. Engagements range from target validation through lead optimisation.
  3. iPSC Quality Control Services: Quality control testing for iPSC lines including Bespoke QC, Standard QC, and Complete QC packages. Provides comprehensive testing ensuring pluripotent nature and genomic stability with full documentation.
  4. iPSC Differentiation Services: Differentiation services transforming pluripotent cells into specialised cell types including neural lineage (cortical, dopaminergic, motor, sensory, GABAergic, glutamatergic neurons; astrocytes, microglia, oligodendrocytes), macrophages, endothelial cells, pericytes, and smooth muscle cells.
  5. PBMC Isolation Service: Standardised peripheral blood mononuclear cell isolation delivering high-quality, high-purity cells for downstream research applications including iPSC reprogramming. Successful isolation within 48 hours of blood withdrawal.
  6. CRISPR Genome Engineering Services: Precision CRISPR genome editing in human iPSCs including gene knockout and isogenic controls, point mutation introduction or correction, reporter cell line generation, large insertions and deletions, regulatory DNA modifications, with comprehensive off-target and QC analysis.
  7. iPSC Repository: Access to characterised iPSC lines from repository for accelerated research. Collection includes lines from autism, bipolar disorder, diabetes, migraine, pain channelopathies, monogenic and sporadic Alzheimer's disease, monogenic and sporadic Parkinson's disease, and healthy controls.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractBespoke QC - Tailored quality control package for basic iPSC characterisation
OtherMulti-year contractStandard QC - Comprehensive package for most research applications
OtherMulti-year contractComplete QC - Full characterisation for publication-ready iPSC lines

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Oxford StemTech product offering

Product offering

Core offering

Oxford StemTech provides fee-for-service induced pluripotent stem cell (iPSC) reprogramming, differentiation, quality control, CRISPR genome engineering, PBMC isolation, and bespoke neurological drug discovery support using its proprietary ReproPlex™ platform, cerebral organoids, assembloids, and multi-electrode array assays. The company sells these services directly to research institutions, pharmaceutical companies, and biotechnology startups on a project-quoted basis.

Product overview

Oxford StemTech provides a comprehensive, end-to-end suite of iPSC-based services built around their proprietary ReproPlex™ platform. The portfolio spans the entire iPSC workflow: PBMC isolation feeds into ReproPlex™ reprogramming, which is followed by iPSC Quality Control and iPSC Differentiation services. The platform is complemented by CRISPR Genome Engineering for gene editing, an iPSC Repository of pre-characterized disease-specific lines, and Bespoke Drug Discovery services for neurological disorders utilizing 2D monolayer, 3D organoid, and assembloid models.

Differentiator

Problem solved

Functional benefit

Brands

  • ReproPlex™: Standardized iPSC reprogramming and characterization platform for generating high-quality induced pluripotent stem cells for research and drug discovery.

Products and services

  • ReproPlex™ iPSC Reprogramming Proprietary, large-scale induced pluripotent stem cell reprogramming service accepting blood (PBMCs, T cells, monocytes), skin biopsies (dermal fibroblasts), and other samples (keratinocytes, brain and intestinal fibroblasts), with reported 98% efficiency and 3–4 month delivery for 100+ donor projects. It is sold to research institutions, pharmaceutical companies, and biotechs needing scalable, high-quality iPSC generation.
  • Bespoke Drug Discovery Custom, partnership-driven drug discovery engagement for neurological and pain disorders, spanning target validation through lead optimisation and using iPSC-derived neurons and glia, monolayer and 3D organoid/assembloid disease models, phenotypic and target-based screening, and multi-electrode array assays. It is delivered to pharmaceutical and biotechnology partners seeking human-relevant cell models for CNS drug discovery.
  • iPSC Quality Control Comprehensive quality control testing services for iPSC lines covering SNP karyotyping and copy number analysis, pluripotency marker assessment (OCT4, SOX2, NANOG, TRA-1-60, SSEA-4), mycoplasma testing, freeze-thaw viability, STR authentication, and trilineage differentiation, offered in Bespoke, Standard, and Complete QC packages with GLP-compliant documentation. It is sold to researchers and pharma partners requiring publication-grade, traceable cell lines.
  • iPSC Differentiation Expert differentiation service transforming iPSCs into specialised cell types, including neural lineages (cortical, dopaminergic, motor, sensory, GABAergic, and glutamatergic neurons; astrocytes, microglia, oligodendrocytes), macrophages, endothelial cells, pericytes, and smooth muscle cells, with cerebral organoids and assembloid 3D brain models. It is sold to researchers and pharma partners needing disease-relevant human cell models.
  • PBMC Isolation Service Standardised peripheral blood mononuclear cell (PBMC) isolation delivering high-purity, high-viability cells within 48 hours of blood withdrawal for use in iPSC reprogramming and downstream research applications. It is sold to laboratories needing reliable input material for stem cell workflows.
  • CRISPR Genome Engineering Precision CRISPR gene editing service in human iPSCs covering gene knockouts and isogenic controls, point mutation introduction or correction, reporter cell line generation, large insertions and deletions, and regulatory DNA modifications, with comprehensive off-target and quality control analysis. It is sold to biotech, pharma, and academic partners for disease modelling, target validation, and precision medicine research.
  • iPSC Repository Access to a collection of characterised iPSC lines from autism, bipolar disorder, diabetes, migraine, pain channelopathies, monogenic and sporadic Alzheimer's and Parkinson's disease, and healthy controls, enabling accelerated research timelines through off-the-shelf patient-specific lines. It is sold to academic and industry researchers needing ready-to-use, disease-specific iPSC lines.

Quantifiable outcome

  • 98% reprogramming efficiency with non-integrating methods
  • +3 more outcomes

Companies that use Oxford StemTech

Customer profile

Segments3 records

Ideal customer profiles3 records

Oxford StemTech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Oxford StemTech partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves11 records

Expansion highlights5 records

Oxford StemTech competitors and assessment

Company assessment

Broad incumbents

  • Cellular Dynamics International (Fujifilm CDI): Acquired by Fujifilm in 2015, CDI is a leading commercial iPSC provider offering iPSC-derived cell lines and services across multiple tissue types. Directly comparable to Oxford StemTech's reprogramming and differentiation services, but with substantially greater scale and capital backing.
  • ReproCELL (now REPROCELL): Established Japanese-headquartered provider of iPSC services, reagents, and drug discovery offerings. Comparable iPSC reprogramming and disease modeling services, with a more global footprint and broader product catalog than Oxford StemTech.
  • Thermo Fisher Scientific (iPSC services): Through its Cell Therapy & iPSC services, Thermo Fisher offers large-scale iPSC reprogramming, differentiation, and characterization services globally. Indirect competitor in the same iPSC service category but as part of a much broader life-sciences portfolio.
  • Lonza (Cell & Gene Services): Global CDMO offering cell therapy and iPSC-related services to pharma and biotech. Comparable at the high end of large-scale iPSC manufacturing and differentiation, but with vastly greater scale, regulatory depth, and pharma relationships.

Direct peers

  • Axol Bioscience: UK-based provider of iPSC-derived cell types and custom iPSC services for neuroscience and drug discovery. Closely comparable in therapeutic focus (neuroscience) and service offering (iPSC-derived neurons, glia, custom reprogramming), making it Oxford StemTech's most direct competitor.
  • Newcells Biotech: UK-based contract research organization specializing in iPSC-derived cell models and assay services for drug discovery, with strong focus on ophthalmology, kidney, and CNS models. Direct peer in geography, business model (CRO services), and iPSC disease modeling.
  • BrainXell: Specializes in iPSC-derived neural cells and neurological disease modeling services, closely aligned with Oxford StemTech's neuroscience/pain focus. Both offer custom neuronal differentiation and drug screening assays for CNS research.

Emerging players

  • Bit Bio: UK-based synthetic biology company providing iPSC-derived human cells at scale for research and drug discovery using proprietary transcription factor-based reprogramming. Comparable in iPSC focus and UK base, but with stronger venture funding and broader cell-type portfolio.
  • Cedars-Sinai iPSC Core / FUJIFILM Cellular Dynamics: Academic and commercial iPSC cores provide reprogramming, banking, and differentiation services for researchers. Comparable as alternative service providers, particularly for academic customers who might otherwise use Oxford StemTech.

Others

  • Stemcell Technologies: Major supplier of cell culture media, reagents, and primary cell products supporting iPSC and stem cell research. Not a direct service competitor but an enabling supplier whose products are used in iPSC workflows alongside Oxford StemTech's services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Oxford StemTech social profiles

Digital presence

Oxford StemTech compliance and trust

Trust signal

Compliance1 record

Oxford StemTech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oxford StemTech leadership team

Management profile

Number of profiles

Profiles3 records

Oxford StemTech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oxford StemTech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford StemTech

What does Oxford StemTech do?

Oxford StemTech provides fee-for-service induced pluripotent stem cell (iPSC) reprogramming, differentiation, quality control, CRISPR genome engineering, PBMC isolation, and bespoke neurological drug discovery support using its proprietary ReproPlex™ platform, cerebral organoids, assembloids, and multi-electrode array assays. The company sells these services directly to research institutions, pharmaceutical companies, and biotechnology startups on a project-quoted basis.

Is Oxford StemTech a public or private company?

Oxford StemTech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Oxford StemTech founded?

Oxford StemTech was founded in 2020. It employs 1 to 10 people.

Where is Oxford StemTech based?

Oxford StemTech is headquartered in Oxford, United Kingdom, in the Europe region.

How does Oxford StemTech make money?

Seven revenue lines are on record. iPSC Reprogramming Services are the primary driver. The others are bespoke Drug Discovery Services, iPSC Quality Control Services, iPSC Differentiation Services, PBMC Isolation Service, CRISPR Genome Engineering Services and iPSC Repository.

Who are Oxford StemTech's main competitors?

Broad incumbents on record are Cellular Dynamics International (Fujifilm CDI), ReproCELL (now REPROCELL), Thermo Fisher Scientific (iPSC services) and Lonza (Cell & Gene Services). Direct peers are Axol Bioscience, Newcells Biotech and BrainXell. Emerging players are Bit Bio and Cedars-Sinai iPSC Core / FUJIFILM Cellular Dynamics. Stemcell Technologies is listed as an others.

Does Oxford StemTech have an API?

No public API is recorded for Oxford StemTech.

What industry is Oxford StemTech in?

Oxford StemTech's product category is Stem Cell Research Services (iPSC Contract Research). Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales